

FILING BY "EXPRESS MAIL" UNDER CFR 1.10	
EV 124615847US Express Mail Label Number	September 1, 2005 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
BURKHART ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2003/010700

FILED: 25 SEPTEMBER 2003

U.S. APPLICATION NO: 10/529,166 ✓

35 USC §371 DATE: 8 AUGUST 2005

FOR: TCELL MEDIATOR/MODULATOR ASSAY BASED UPON TCELL
RESTRICTED TRANSGENIC MOUSE

MS: PCT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

COMMUNICATION IN RESPONSE TO THE
NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. § 371


Sir:

On August 4, 2005, the USPTO issued the Notification of Missing Requirements Under 35 U.S.C. § 371, a copy of which is enclosed.

This undersigned submitted the executed Declaration to the USPTO on August 8, 2005 in a Second or Subsequent Submission of Items Concerning a Filing Under 35 U.S.C. § 371. Enclosed please find a copy this Second or Subsequent Submission, a copy of the executed Declaration, and a copy of the date stamped postcard from the USPTO acknowledging receipt by the PCT/PTO on August 8, 2005.

Because Applicants submitted the executed Declaration on August 8, 2005 with authorization to charge the \$130 late fee and any additional fees to our Deposit Account, no fee is required.

Respectfully submitted,


Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614
Date: 9/1/05



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/529,166	Christoph Burkhardt	PD/4-32516A

1095
 NOVARTIS
 CORPORATE INTELLECTUAL PROPERTY
 ONE HEALTH PLAZA 104/3
 EAST HANOVER, NJ 07936-1080

INTERNATIONAL APPLICATION NO.	
PCT/EP03/10700	
I.A. FILING DATE	PRIORITY DATE
09/25/2003	09/26/2002

CONFIRMATION NO. 4328
 371 FORMALITIES LETTER



OC000000016687865


GCH

Date Mailed: 08/04/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 03/24/2005
- Copy of the International Search Report filed on 03/24/2005
- Preliminary Amendments filed on 03/24/2005
- Information Disclosure Statements filed on 03/24/2005
- U.S. Basic National Fees filed on 03/24/2005
- Priority Documents filed on 03/24/2005



The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- \$130 Surcharge for providing the oath or declaration later than 30 months from the priority date (37 CFR 1.492(e)) is required.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

- \$130 Late oath or declaration Surcharge.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

DOCKETED FOR: Oct. 4, 2005

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

PATRICIA A BOOKER

Telephone: (703) 308-9140 EXT 204

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/529,166	PCT/EP03/10700	PD/4-32516A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1	
<div style="font-size: 1.5em; font-family: cursive;">EV 72461573105</div> <div style="font-size: 0.8em;">Express Label Number</div>	<div style="font-size: 1.5em; font-family: cursive;">August 8, 2005</div> <div style="font-size: 0.8em;">Date of Deposit</div>

Form PTO-1390-MOD (REV 10-96)		U. S. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER PD/4-32516A
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/529,166
INTERNATIONAL APPLICATION NO. PCT/EP2003/010700	INTERNATIONAL FILING DATE 25 September 2003 (25.09.03)	PRIORITY DATE CLAIMED 26 September 2002 (26.09.02)	
TITLE OF INVENTION TCELL MEDIATOR/MODULATOR ASSAY BASED UPON TCELL RESTRICTED TRANSGENIC MOUSE			
APPLICANT(S) FOR DO/EO/US BURKHART ET AL.			

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau. (See Form PCT/IB/308)
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included.

11. ☒ A Supplemental Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ An Application Data Sheet under 37 CFR 1.76.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.
18. ☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4)
19. ☐ A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)
10/529,166

INTERNATIONAL APPLICATION NO.
PCT/EP2003/010700

ATTORNEY'S DOCKET NUMBER
PD/4-32516A

The following fees are submitted:

21. Basic national fee. \$

22. Examination Fee

If International preliminary examination report was prepared by USPTO
and all claims satisfy provisions of PCT Article 33(1)-(4) \$

All other situations. \$

23. Search fee

If Search fee (37 CFR 1.445(a)(2)) has been paid on the international
application to the USPTO as an International Searching Authority. \$

If International Search Report was prepared and provided to the Office. . . \$

All other situations. \$

TOTAL OF 21, 22 AND 23 =

CALCULATIONS PTO USE
ONLY

\$ 0

Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.

Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE
- 100 =	/50 =	X	\$ 250

Surcharge of \$130 for furnishing the oath of declaration later than ☒ 30 months from the earliest claimed priority date (37 CFR 1.492(e)). \$ 130

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	- 20 =	X	\$ 50
Independent claims	- 3 =	X	\$ 200
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 360

TOTAL OF ABOVE CALCULATIONS = \$ 130

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28). \$

SUBTOTAL = \$ 130

Processing fee of \$130 for furnishing the English translation later than ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)). + \$

TOTAL NATIONAL FEE = \$ 130

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property + \$

TOTAL FEES ENCLOSED = \$ 130


Amount to be: refunded	\$
charged	\$

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$130 to cover the above fees. A duplicate copy of this form is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

Send all correspondence to the address associated with Customer No. 001095, which is currently:

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080


Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666
(862) 778-2614

DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION☒ Original☐ Supplemental☐ Substitute

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

TCELL MEDIATOR/MODULATOR ASSAY BASED UPON TCELL RESTRICTED TRANSGENIC MOUSE

the specification of which:

☐ is attached hereto.

☐ was filed on _____ as Application No. _____
(day/month/year)

and, if this box (☐) contains an *

☐ was amended on _____
(day/month/year)

☒ was filed as Patent Cooperation Treaty international Application No.

PCT/EP 03/10700 on 25/09/03
(day/month/year)

and, if this box (☐) contains an *

☐ entered the national stage in the United States and was accorded Application No. _____

and, if this box (☐) contains an *

☐ was amended, subsequent to entry into the national stage, on _____
(day/month/year)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) specifically referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose information which is material to patentability as defined in 37 C.F.R. 1.56, including, for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or Patent Cooperation Treaty international filing date of the continuation-in-part application.

BEST AVAILABLE COPY

I hereby claim the benefit under 35 U.S.C. 119(a)-(d) or (f) or 365(b) of any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate listed below and under 35 U.S.C. 365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	PRIORITY CLAIMED
-------------------------------	-----------------	---------------------------------	------------------

☐ Yes ☐ No

☐ Yes ☐ No

☐ Yes ☐ No

☐ Yes ☐ No

☐ Yes ☐ No

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

APPLICATION NO.	FILING DATE (day/month/year)
-----------------	---------------------------------

60/413706 26/09/02

60/413702 26/09/02

60/413703 26/09/02

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s) listed below and under 35 U.S.C. 365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below:

United States Application No.	United States Filing Date (day/month/year)	Status (Pending, Abandoned or U.S. Patent No.)	International Application No. and Filing Date (day/month/year)
----------------------------------	--	--	--

I hereby appoint all the registered practitioners associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If this box (☐) contains an x ☒, I hereby authorize the registered practitioners associated with Customer No. 001095 and any others acting on my behalf to take any action relating to this application based on communications from Corporate Intellectual Property of Novartis International AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please send all correspondence relating to this application to the address associated with Customer No. 001095.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole
or first joint inventor

Christoph BURKHART

Inventor's signature



Date

19/04/2005
(day/month/year)

Residence

1130 Vienna, Austria,

Citizenship

Austria

Post Office Address

**Stuweekengasse 9, 1130 Vienna,
Austria**

Full name of second
joint inventor, if any

Ekke LIEHL

Inventor's signature

Date

(day/month/year)

Residence

2371 Hinterbrühl, Austria

Citizenship

Germany

Post Office Address

**Badgasse 12/2, 2371 Hinterbrühl,
Austria**

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Full name of third
joint inventor, if any

Peter MAYER

Inventor's signature

Date

(day/month/year)

Residence

1130 Vienna, Austria

Citizenship

Austria

Post Office Address

**Trauttmannsdorffgasse 32/4, 1130
Vienna, Austria**

Full name of fourth
joint inventor, if any

Inventor's signature

Date

(day/month/year)

Residence

Citizenship

Post Office Address

Full name of fifth
joint inventor, if any

Inventor's signature

Date

(day/month/year)

Residence

Citizenship

Post Office Address

DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION☒ Original☐ Supplemental☐ Substitute

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

TCELL MEDIATOR/MODULATOR ASSAY BASED UPON TCELL RESTRICTED TRANSGENIC MOUSE

the specification of which:

☐ is attached hereto.

☐ was filed on _____ as Application No. _____
(day/month/year)

and, if this box (☐) contains an *

☐ was amended on _____
(day/month/year)

☒ was filed as Patent Cooperation Treaty international Application No.

PCT/EP 03/10700 on 25/09/03
(day/month/year)

and, if this box (☐) contains an *

☐ entered the national stage in the United States and was accorded Application No. _____

and, if this box (☐) contains an *

☐ was amended, subsequent to entry into the national stage, on _____
(day/month/year)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) specifically referred to above and, if this application was filed as a Patent Cooperation Treaty international application, by any amendments made during the international stage (including any made under Patent Cooperation Treaty Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose information which is material to patentability as defined in 37 C.F.R. 1.56, including, for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or Patent Cooperation Treaty international filing date of the continuation-in-part application.

I hereby claim the benefit under 35 U.S.C. 119(a)-(d) or (f) or 365(b) of any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate listed below and under 35 U.S.C. 365(a) of any Patent Cooperation Treaty international application(s) designating at least one country other than the United States listed below and have also listed below any foreign application(s) for patent, inventor's certificate or plant breeder's right certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application the priority of which is claimed for that subject matter:

COUNTRY/REGION (OR P.C.T.)	APPLICATION No.	FILING DATE (day/month/year)	PRIORITY CLAIMED
-------------------------------	-----------------	---------------------------------	------------------

<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

APPLICATION NO.	FILING DATE (day/month/year)
-----------------	---------------------------------

60/413706	26/09/02
60/413702	26/09/02
60/413703	26/09/02

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s) listed below and under 35 U.S.C. 365(c) of any Patent Cooperation Treaty international application(s) designating the United States listed below:

United States Application No.	United States Filing Date (day/month/year)	Status (Pending, Abandoned or U.S. Patent No.)	International Application No. and Filing Date (day/month/year)
----------------------------------	--	--	--

I hereby appoint all the registered practitioners associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

If this box (☐) contains an x ☒, I hereby authorize the registered practitioners associated with Customer No. 001095 and any others acting on my behalf to take any action relating to this application based on communications from Corporate Intellectual Property of Novartis International AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please send all correspondence relating to this application to the address associated with Customer No. 001095.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole
or first joint inventor

Christoph BURKHART

Inventor's signature

Date

(day/month/year)

Residence

1130 Vienna, Austria,

Citizenship

Austria


Post Office Address

**Stuweekengasse 9, 1130 Vienna,
Austria**

Full name of second
joint inventor, if any

Ekke LIEHL

Inventor's signature



Date

10. 3. 2005
(day/month/year)

Residence

2371 Hinterbrühl, Austria

Citizenship

Germany

Post Office Address

**Badgasse 12/2, 2371 Hinterbrühl,
Austria**

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Full name of third
joint inventor, if any

Peter MAYER

Inventor's signature

P. Mayer

Date

12.4.2005

(day/month/year)

Residence

1130 Vienna, Austria

Citizenship

Austria

Post Office Address

**Trauttmannsdorffgasse 32/4, 1130
Vienna, Austria**

Full name of fourth
joint inventor, if any

Inventor's signature

Date

(day/month/year)

Residence

Citizenship

Post Office Address

Full name of fifth
joint inventor, if any

Inventor's signature

Date

(day/month/year)

Residence

Citizenship

Post Office Address

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV724615731US
Express Mail Label NumberAugust 8, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BURKHART ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2003/010700

FILED: 25 SEPTEMBER 2003

U.S. APPLICATION NO: 10/529,166

35 USC §371 DATE: Not Yet Known

FOR: TCELL MEDIATOR/MODULATOR ASSAY BASED UPON TCELL
RESTRICTED TRANSGENIC MOUSE**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is supplemental to the Information Disclosure Statement filed March 24, 2005. Since it is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614
Date: 8/8/05

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. D. [REDACTED] ET NO.
PD/4-32516A
APPLICATION NO.
10/9 [REDACTED]
APP. NO. [REDACTED]
BURKHART ET AL.
FILING DATE
Herewith

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	0 701 607	1/10/01	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	94/28122	12/8/94	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	95/32285	11/30/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	97/08303	3/6/97	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	99/16867	4/8/99	WO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Brinkmann et al., "FTY720: Altered Lymphocyte Traffic Results in Allograft Protection", Transplantation, Vol. 72, No. 5, pp. 764-769 (2001).
	AS	Caruso et al., "Flow Cytometric Analysis of Activation Markers on Stimulated T Cells and Their Correlation with Cell Proliferation", Cytometry, Vol. 27, pp. 71-76 (1997).
	AT	Gibbons et al., "CD69 Expression After Antigenic Stimulation", Cytometry, Vol. 23, pp. 260-261 (1996).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PD/4-32516A
APPLICATION NO.
10/5
APPLICANT
BURKHART ET AL.
FILING DATE
Herewith

Group

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BA	02/00252	1/3/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BB	02/059263	8/1/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BC						<input type="checkbox"/>	<input type="checkbox"/>
	BD						<input type="checkbox"/>	<input type="checkbox"/>
	BE						<input type="checkbox"/>	<input type="checkbox"/>
	BF						<input type="checkbox"/>	<input type="checkbox"/>
	BG						<input type="checkbox"/>	<input type="checkbox"/>
	BH						<input type="checkbox"/>	<input type="checkbox"/>
	BI						<input type="checkbox"/>	<input type="checkbox"/>
	BJ						<input type="checkbox"/>	<input type="checkbox"/>
	BK						<input type="checkbox"/>	<input type="checkbox"/>
	BL						<input type="checkbox"/>	<input type="checkbox"/>
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>
	BR						<input type="checkbox"/>	<input type="checkbox"/>
	BS						<input type="checkbox"/>	<input type="checkbox"/>
	BT						<input type="checkbox"/>	<input type="checkbox"/>
	BU						<input type="checkbox"/>	<input type="checkbox"/>
	BV						<input type="checkbox"/>	<input type="checkbox"/>
	BW						<input type="checkbox"/>	<input type="checkbox"/>
	BX						<input type="checkbox"/>	<input type="checkbox"/>
	BY						<input type="checkbox"/>	<input type="checkbox"/>
	BZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PD/4-32516A
APPLICATION NO.
10/5
APPLICANT
BURKHART ET AL.
FILING DATE
Herewith

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

CA	Hari et al., "T Cell Involvement in Cutaneous Drug Eruptions", Clinical and Experimental Allergy, Vol. 31, pp. 1398-1408 (2001).
CB	Huegin et al., "Suppression by Cyclosporin A of Murine T-Cell-Mediated Immunity Against Viruses in Vivo and in Vitro", Cellular Immunology, Vol. 90, pp. 464-473 (1985).
CC	Huseby et al., "A Pathogenic Role for Myelin-Specific CD8 ⁺ T Cells in a Model for Multiple Sclerosis", J. Exp. Med., Vol. 194, No. 5, pp. 669-676 (2001).
CD	Jenkins et al., "In Vivo Activation of Antigen-Specific CD4 T Cells", Annu. Rev. Immunol. Vol. 19, pp. 23-45 (2001).
CE	Morris, "Cyclosporine, FK506 and Other Drugs in Organ Transplantation", Current Opinion in Immunology, Vol. 3, pp. 748-751 (1991).
CF	Pinschewer et al., "FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory", The Journal of Immunology, Vol. 164, pp. 5761-5770 (2000).
CG	Rosenberg et al., "Cellular Basis of Skin Allograft Rejection: An In Vivo Model of Immune-Mediated Tissue Destruction", Annu. Rev. Immunol., Vol. 10, pp. 333-358 (1992).
CH	Skinner et al., "Cutting Edge: In Situ Tetramer Staining of Antigen-Specific T Cells in Tissues", The Journal of Immunology, Vol. 165, pp. 613-617 (2000).
CI	Valitutti et al., "Sustained Signaling Leading to T Cell Activation Results from Prolonged T Cell Receptor Occupancy Role of T Cell Actin Cytoskeleton", J. Exp. Med., Vol. 181, pp. 577-584 (1995).
CJ	Wong et al., "Identification of an MHC Class I-Restricted Autoantigen in Type 1 Diabetes by Screening an Organ-Specific cDNA Library", Nature Medicine, Vol. 5, No. 9, pp. 1026-1031 (1999).
CK	
CL	
CM	
CN	

EXAMINER


DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Case No. PD/4-516A
Application No. 10/529,166
Mailing Date: August 8, 2005
Due Date: _____
Express Mail No.: EV 724615731 US

The Patent & Trademark Office acknowledges, and has stamped hereon the date of receipt of the items checked below:

- ☐ Amendment/Response/Letter - Fee \$ _____
☐ Appln. Filing Papers - Fee \$ _____
 ☐ PCT National Stage
 ☐ Provisional Application
 ☐ RCE ☐ DIV ☐ CONT ☐ CIP
 ☐ Specification _____ Pg's
☒ Executed/Unexecuted Decl. - Fee \$ 130
 ☐ Missing Parts/Missing Req. _____
☐ Preliminary Amendment _____
☐ Claim of Priority ☐ Certified Copy(s) _____
☐ Amendment After Final _____
☐ Notice of Appeal - Fee \$ _____
☐ Appeal Brief - Fee \$ _____
☐ Issue Fee Payment \$ _____
☐ Assignment Rec. Req. - Fee \$ _____
☐ Formal Drawings _____ Pg's
☒ IDS 1 Pg's - Fee \$ _____
☒ PTO-1449 Form 3 Pg's + 20 References
☐ Pet. for Ext. of Time - Fee \$ _____
☐ Application Data Sheet
☐ Seq. Listings _____ Pg's/Seq. Disk
☐ _____
☒ CH Initials



JC06 Rec'd PCT/PTO 08 AUG 2005